Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NPPB (5-nitro-2-(3-phenylpropylamino)benzoic acid) is a widely used, broad-spectrum chloride channel blocker and pharmacological research tool. It inhibits multiple chloride conductance pathways, including the cystic fibrosis transmembrane conductance regulator (CFTR), calcium-activated chloride channels (CaCCs / TMEM16), volume-regulated anion channels (VRACs), and ClC chloride channels (such as ClC-K2 and ClC-3). In addition to its chloride channel blocking activity, NPPB acts as an agonist of the G-protein coupled receptor GPR35 and exhibits protonophoric activity, uncoupling mitochondrial oxidative phosphorylation at higher concentrations. It is primarily utilized as a laboratory reagent for in vitro and ex vivo electrophysiological and ion transport studies.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on NPPB.